|
|
|
| Value of High-Frequency Ultrasound-Guided Core Needle Biopsy Combined with Tumor Markers in Diagnosing Benign and Malignant Breast Masses |
| DONG Yan |
| Department of Ultrasound Medicine, Fanxian People's Hospital, Puyang Henan 457500 |
|
|
|
|
Abstract 【Objective】 To evaluate the diagnostic value of high-frequency ultrasound-guided core needle biopsy combined with tumor marker testing for distinguishing benign from malignant breast masses. 【Methods】 A total of 98 patients with breast masses admitted to our hospital between January 2021 and June 2025 were enrolled. Among them, 51 patients diagnosed with breast cancer by postoperative pathological examination were assigned to the observation group, and 47 patients with benign breast lesions were assigned to the control group. All patients underwent high-frequency ultrasound-guided core needle biopsy and measurement of carbohydrate antigen 125 (CA125), carbohydrate antigen 15-3 (CA15-3), and alpha-fetoprotein (AFP) levels. The diagnostic performance of the combination of high-frequency ultrasound-guided core needle biopsy with CA125, CA15-3, and AFP was assessed using receiver operating characteristic (ROC) curves. 【Results】 High-frequency ultrasound-guided core needle biopsy revealed 47 cases of breast cancer and 44 cases of benign breast lesions. The levels of CA125, CA15-3, and AFP in the observation group were significantly lower than those in the control group (P<0.05). ROC curve analysis showed that the sensitivity and specificity of high-frequency ultrasound-guided core needle biopsy combined with detection of CA125, CA15-3, and AFP for diagnosing benign versus malignant breast masses were 94.1% and 97.9%, respectively, with an area under the ROC curve (AUC) of 0.982. 【Conclusion】 The combination of high-frequency ultrasound-guided core needle biopsy with CA125, CA15-3, and AFP testing significantly improves the sensitivity and specificity in diagnosing the nature of breast masses and holds substantial clinical value.
|
|
Received: 19 December 2025
|
|
|
|
|
|
[1] 马云瑶,薛超,刘海涛,等. 弥散加权成像联合血清CEA、TFF1、sE-cadherin对乳腺良恶性肿块的鉴别价值研究[J].现代生物医学进展,2023,23(17):3273-3277.
[2] 张秀丽. 高频彩色多普勒超声联合BI-RADS分级在临床鉴别诊断良恶性乳腺结节中的应用价值[J].中外医学研究,2024,22(11):58-61.
[3] 翟晓利,章艳斐,王利霞. 超声引导下粗针穿刺活检标本p53、PD-L1检测在乳腺癌中的应用价值[J].中华内分泌外科杂志,2023,17(3):348-352.
[4] 刘逸群,刘玉洁,张梦红,等. 超声弹性成像联合癌胚抗原CEA、CA15-3和CA125对乳腺癌患者的早期诊断价值[J].中国实验诊断学,2024,28(8):928-930.
[5] 田秀丽,李劲松. 超声检查联合血清CEA、AFP在乳腺癌鉴别诊断中的应用价值[J].医学临床研究,2024,41(1):85-87.
[6] 何瑞红,李立,钱伟军. DCE-MRI、多b值DWI结合CA15-3、CEA对乳腺癌及肿块型浆细胞性乳腺炎的鉴别诊断价值研究[J].中国CT和MRI杂志,2023,21(6):89-92.
[7] 高素娟,邹莹莹,孟繁繁. 高频超声联合血清CA125、CA19-9、CYFRA21-1对乳腺肿块的鉴别诊断价值[J].黑龙江医学,2025,49(2):201-203.
[8] 刘辉,高曼丽,谢晴晴,等. 乳腺癌超声多模态成像参数与CA15-3、CA125表达相关性及诊断价值研究[J].医学影像学杂志,2024,34(8):74-78.
[9] 陈爽冉,岳玉桃,张芳,等. 高频超声检查结合粗针穿刺活检在鉴别乳腺癌中的应用及其与血清CA125、CA15-3的相关性[J].实用癌症杂志,2022,37(2):315-318.
[10] 沈勤红. 高频超声引导下粗针穿刺活检及肿瘤标志物检测在乳腺肿块良恶性鉴别诊断中的价值研究[J].中国现代药物应用,2024,18(5):68-71. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(7): 1159-1162. |
|
|
|
|
2026, Vol. 43 
